Shares in AbbVie rose in the company's first day of trading on the New York Stock Exchange Wednesday, NYSE data shows. The stock advanced from an opening price of $34.92 to $35.12 at market close.
Shortly before the debut, officials from the firm rang the NYSE's opening bell in the exchange's first trading day of this year.
AbbVie is a publicly traded spinoff of health care concern Abbott Laboratories . It specializes in the manufacture and sale of branded drugs, particularly the state-of-the-art, anti-inflammatory medication HUMIRA. According to a press release the company issued to mark its stock market debut, it has an estimated $18 billion in annual revenues.
The article AbbVie Rises on Stock Market Debut originally appeared on Fool.com.
Eric Volkman has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.